Pharmaceutical Product Development, LLC (PPD) has been recognized recently in three different aspects of its operations.

Pharmaceutical and biotech executives surveyed by Life Science Leader for the magazine's 2019 CRO Leadership awards ranked Wilmington-based PPD high for excellence in clinical research. This is the eighth consecutive year that the company has received this distinction, according to a news release.

PPD earned honors in three distinct categories of clinical research, including for its capabilities, compatibility and expertise.

In addition, based on data from a separate market survey of pharma companies, PPD was recognized with an individual attribute award for "providing clients with robust data analytics technology to inform decision-making in clinical research," the release stated.

PPD also was named the winner of the CRO Quality Award from the Association of Clinical Research Professionals (ACRP) and The Avoca Group during the ACRP annual conference in April.

PPD’s selection, according to a news release, was based on The Avoca Group’s "independent research with investigator sites, which recognized PPD’s industry leadership on quality outcomes in the design, execution and oversight of clinical trials, as well as strong communication and partnership skills."

PPD has strategic relationships with sites and site networks across the globe, providing access to industry-leading numbers of patients and high-performing sites, the release stated, adding that "Leveraging these partnerships allows for efficient study startup and execution."

The Avoca Group, which conducted its research over an eight-week period in early 2019, was quoted in the release as reporting that "site personnel rated PPD highly for responsive, high-quality communication, clinical research associates with strong knowledge of the study protocol and several aspects of study execution, including reliability of clinical supplies, ease of use of the electronic data capture (EDC) system and study closeout."

The third distinction was earned by Optimal Research, a service of PPD’s Accelerated Enrollment Solutions (AES) business unit. PPD announced recently that Optimal Research was named the top clinical trial network at the 12th annual Vaccine Industry Excellence Awards during the 2019 World Vaccine Congress in Washington, D.C.

The Vaccine Industry Excellence Awards celebrate the outstanding achievements of organizations and individuals setting high standards of excellence and advocacy in the vaccine industry.

"Optimal’s Vaccine Centers of Excellence is the world’s largest vaccine site network, accentuated by accelerated patient enrollment services, advanced lab capabilities including peripheral blood mononuclear cells (PBMC) processing, and specialized vaccine services – all delivered under a results-based contracting model that offers cost and time certainty in trial delivery," PPD's news release stated.

“This recognition by industry peers reflects our Vaccine Centers of Excellence’s success in supporting multiple and diverse clinical phase and outcomes trials,” Krystyna Kowalczyk, chief operating officer for Optimal Oncology and Vaccines Services, said in the release. “This award acknowledges our team’s expertise in helping clients quickly enroll patients and maintain extremely high retention rates."